High-dose chemotherapy with autologous stem cell rescue (HDCT) is currently under investigation as a potential therapy for patients with stage III HER2-negative breast cancer with homologous recombination deficiency (HRD). Here, ERBB2 is linked to hyperinsulinemic hypoglycemia, familial, 4.